Warren Buffett Comments on Valeant Pharma (VRX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Valeant (VRX) 10-K Not Enough to Bring Back the Bulls or Scare The Bears - BMO Capital
May 2, 2016 9:56 AM EDTBMO Capital analyst Alex Arfaei reiterated a Market Perform rating and lowered his price target on Valeant Pharmaceuticals (NYSE: VRX) to $44.00 (from $66.00), saying the 10K is not enough to bring back the bulls or scare the bears.
Arfaei commented, "The good news was that we didnt find any new smoking guns in the 10-K. Valeant has averted technical default on its debt, and based on our... More
Valeant's (VRX) Debt Covenants Remain a Concern After 10K Filing - Piper Jaffray
May 2, 2016 7:43 AM EDTPiper Jaffray analyst, David Amsellem, noted that Valeant's (NYSE: VRX) 10K for 2015 contained one kernel of good news: it cured the default on its senior notes related to the late filing. Unfortunately that was "the only piece of good news". Here are the problems:
Wholesaler inventory... More
